Literature DB >> 10737538

Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney.

K K Donnahoo1, D R Meldrum, R Shenkar, C S Chung, E Abraham, A H Harken.   

Abstract

PURPOSE: Acute tubular necrosis (ATN) and the ensuing renal failure induced by ischemia and reperfusion injury (I/R) remain a major cause of morbidity and mortality among patients in the intensive care unit. Although it is well established that exogenous tumor necrosis factor-alpha (TNF) induces renal injury, it remains unknown whether ischemia and/or reperfusion activates the signaling mechanisms required for renal TNF production. We hypothesized that ischemia and/or reperfusion would activate the oxidant sensitive TNF transcription factor, nuclear factor kappa B (NFkappaB), and thereby lead to renal TNF production.
MATERIALS AND METHODS: Male Sprague-Dawley rats were anesthetized with sodium pentobarbital, after which various periods of renal ischemia, with or without reperfusion, were induced in rats. At different time intervals, kidneys were harvested and NFkappaB activation (electrophoretic mobility shift assay), TNF mRNA content (RT-PCR), and TNF bioactivity (WEHI-164 cell clone cytotoxicity assay) were determined.
RESULTS: Results indicate that 15 minutes of ischemia alone activates NFkappaB, whereas peak activation occurred at 30 minutes of ischemia alone. NFkappaB remained activated through 60 minutes reperfusion. Thirty minutes of ischemia is required to induce renal TNF mRNA production; however, renal TNF protein expression and bioactivity peaked following 1 hour of ischemia and 2 hours reperfusion.
CONCLUSIONS: These results are the initial demonstration that renal ischemia, with or without reperfusion, activates the TNF transcription factor NFkappaB and increases TNF bioactivity in the kidney.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737538

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  38 in total

1.  AS-IV protects against kidney IRI through inhibition of NF-κB activity and PUMA upregulation.

Authors:  Yan Xin; Gang Li; Hongxiu Liu; Dengbin Ai
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

3.  Ischaemic/reperfusion injury: Role of infliximab.

Authors:  Atul Bagul
Journal:  World J Transplant       Date:  2012-06-24

Review 4.  AKI associated with cardiac surgery.

Authors:  Robert H Thiele; James M Isbell; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

5.  Peptidyl arginine deiminase-4 exacerbates ischemic AKI by finding NEMO.

Authors:  May M Rabadi; Sang Jun Han; Mihwa Kim; Vivette D'Agati; H Thomas Lee
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-03

6.  Type I interferon pathway mediates renal ischemia/reperfusion injury.

Authors:  Maria Cecilia S Freitas; Yoichiro Uchida; Charles Lassman; Gabriel M Danovitch; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Transplantation       Date:  2011-07-27       Impact factor: 4.939

7.  Acute kidney injury as a causal factor in mortality associated with hepatorenal syndrome.

Authors:  Priya Deshpande; Katherine Rausa; Jeffrey Turner; Mark Johnson; Ladan Golestaneh
Journal:  Hepatol Int       Date:  2011-03-27       Impact factor: 6.047

Review 8.  The Fetal-Maternal Immune Interface in Uterus Transplantation.

Authors:  Jasper Iske; Abdallah Elkhal; Stefan G Tullius
Journal:  Trends Immunol       Date:  2020-03       Impact factor: 16.687

Review 9.  Slit2-Robo signaling in inflammation and kidney injury.

Authors:  Swasti Chaturvedi; Lisa A Robinson
Journal:  Pediatr Nephrol       Date:  2014-04-29       Impact factor: 3.714

10.  Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy.

Authors:  Sang Won Park; Sean W C Chen; Mihwa Kim; Kevin M Brown; Jay K Kolls; Vivette D D'Agati; H Thomas Lee
Journal:  Lab Invest       Date:  2010-08-09       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.